

XII
SOCIETÀ
CONGRESSO

NAZIONALE
IG-IBD

ADVANCES IN IBD

SALA CONCORDIA
27-29 NOVEMBRE

FACULTY

Allocca Marinagela, *Milano*
Annese Vito, *Milano*
Ardizzone Sandro, *Milano*
Bertani Lorenzo, *Pontedera (PI)*
Bertin Luisa, *Padova*
Bezzio Cristina, *Rozzano (MI)*
Bodini Giorgia, *Genova*
Buda Andrea, *Feltre (BL)*
Calabrese Emma, *Roma*
Cappello Maria, *Palermo*
Caprioli Flavio Andrea, *Milano*
Cazzagon Nora, *Padova*
Centanni Lucia, *Milano*
D'Arcangelo Giulia, *Milano*
Danese Silvio, *Milano*
Daperno Marco, *Torino*
Di Vincenzo Federica, *Roma*
Dragoni Gabriele, *Firenze*
Facciotti Federica, *Milano*
Faggiani Ilaria, *Milano*
Fanizzi Fabrizio, *Milano*
Fantini Massimo Claudio, *Monsestato (CA)*
Festa Stefano, *Roma*
Fiorino Gionata, *Roma*
Gallo Gaetano, *Milano*
Gionchetti Paolo, *Bologna*
Gravina Antonietta Gerarda, *Napoli*
Iannucci Andrea, *Roma*
Innocenti Tommaso, *Firenze*
Jairath Vipul, *London (CA)*
Lenti Marco Vincenzo, *Pavia*
Macaluso Fabio Salvatore, *Palermo*

Maccioni Francesca, *Roma*
Maconi Giovanni Egidio, *Milano*
Massironi Sara, *Monza*
Melotti Laura, *Bologna*
Nardone Olga Maria, *Napoli*
Noviello Daniele, *Milano*
Onali Sara, *Monsestato (CA)*
Orlando Ambrogio, *Palermo*
Pane Cesare, *Chieti*
Parello Simone, *Roma*
Pellegrino Raffaele, *Napoli*
Principi Mariabeatrice, *Bari*
Privitera Giuseppe, *Milano*
Pugliese Daniela, *Roma*
Renna Sara, *Palermo*
Ribaldone Davide Giuseppe, *Torino*
Rizzello Fernando, *Bologna*
Rottoli Marco, *Bologna*
Saibeni Simone, *Rho (MI)*
Savarino Edoardo Vincenzo, *Padova*
Scarallo Luca, *Firenze*
Solitano Virginia, *Milano*
Stalla Francesco Maria, *Torino*
Testa Anna, *Napoli*
Torres Joana, *Lisbon (PG)*
Troisi Sara, *Chieti*
Variola Angela, *Negrar (VR)*
Vecchi Maurizio, *Milano*
Viola Anna, *Messina*
Zabana Abdo Yamile, *Barcelona (ES)*
Zingone Fabiana, *Padova*

14.00-14.30 **Opening remarks**
M.C. Fantini
AMICI Italia, M.I.Cro. Italia Odv

LECTURE

Introduction: Presentazione Fondazione IG-IBD
M.C. Fantini, S. Ardizzone

14.30-15.00 **The scientific relevance of the ENEIDA registry**
Y. Zabana Abdo

SESSION I ORAL COMMUNICATIONS

Chairs: G.E. Maconi, A. Viola

15.00-15.10 **Deep learning for automated and objective in vivo assessment of intestinal epithelial barrier integrity in IBD using probe-based confocal laser endomicroscopy**
D. Noviello

15.10-15.20 **The IUS-IBD scores calculator: an ios & android app to promote and facilitate the use of intestinal ultrasound scores in IBD patients**
F.M. Stalla

PROGRAMMA

Thursday, 27 November

- 15.20-15.30 **Intestinal ultrasound scan in acute severe ulcerative colitis in children: a multicenter prospective study on behalf of the Porto IBD Working Group of Espghan**
L. Scarallo
- 15.30-15.40 **Learning curve in intestinal ultrasound: advancing from basic skills to advanced competencies - insights from the IUS IG-IBD master program**
L. Bertin
- 15.40-15.50 **Use of a multimodal large language model for the automatic scoring of the Mayo endoscopic score in colonoscopy frames of ulcerative colitis: a human-blinded diagnostic accuracy study of generative artificial intelligence**
A.G. Gravina
- 15.50-16.00 **Predictors of suboptimal bowel preparation in patients with Inflammatory Bowel Disease undergoing colonoscopy: preliminary results from the multicentric IBD-win colon study**
R. Pellegrino
- 16.00-16.30 *Coffee break*

**SESSION II MULTIDISCIPLINARY THINKING OF ACUTE
SEVERE ULCERATIVE COLITIS**

Chairs: G. Gallo, F. Rizzello

- 17.45-18.05 **Medical: getting started**
S. Festa
- 18.05-18.25 **Medical: ready to rescue and maintain**
C. Bezzio
- 18.25-18.45 **Surgical: ready to act**
M. Rottoli
- 18.45-19.00 **Discussion**

PROGRAMMA

Friday, 28 November

07.30-08.20

EARLY BREAKFAST MEETINGS

EXTRA ECM

Sala POLISSENA B

Travelling with IBD, vaccination in IBD

O.M. Nardone, M. Principi

Sala POLISSENA C

Taboo in IBD

G. Privitera, A. Variola

LECTURE

Introduction: M. Cappello

08.30-09.00

Checkpoint inhibitor-induced colitis

M.V. Lenti

SESSION III ORAL COMMUNICATIONS

Chairs: P. Gionchetti, S. Renna

09.00-09.10

Sequencing Jak-inhibitors in ulcerative colitis: effectiveness and safety of switching within treatment class

T. Innocenti

09.10-09.20

Real-world effectiveness and safety of Risankizumab in Crohn's disease: a single-center experience

L. Centanni

09.20-09.30

Real-world effectiveness and safety of Mirikizumab in ulcerative colitis patients

L. Melotti

09.30-09.40 **Switching to subcutaneous administration may offer more profound remission compared to intensified intravenous therapy in patients with Inflammatory Bowel Disease and partial response following induction with intravenous vedolizumab: the PRIVEDO study**

F.S. Macaluso

09.40-09.50 **Treat-to-target optimization is effective on endoscopic and histologic outcomes in a real-life cohort of ulcerative colitis – the TACTIC study**

G. Privitera

09.50-10.00 **Effectiveness and safety of rescue medical therapy for children developing acute severe colitis after infliximab failure (RESCUC): a multi-center retrospective study by the Porto Group.**

G. D'Arcangelo

10.00-10.30 *Coffee break*

SESSION IV IUS REPLACING ENDOSCOPY AND MRE?

Chairs: A. Buda, E. Calabrese

11.15-11.35 **IUS: what I can report, what I can't?**

M. Allocca

11.35-11.55 **Endoscopy: sense and non-sense of endoscopic scores**

M. Daperno

11.55-12.15 **MRE: when is it necessary, when is not?**

F. Maccioni

12.15-12.45 **Discussion**

12.45-13.45 **Lunch**

15.00-16.00 **SESSION V ORAL COMMUNICATIONS**

Chairs: F. Facciotti, F. Zingone

15.00-15.10 **Single-cell dissection of peripheral CD3⁺ T cell repertoire remodeling induced by advanced combination treatment in Inflammatory Bowel Disease**

V. Solitano

15.10-15.20 **The HNF4A-IMP3-IL23R axis drives gut inflammation and anti-TNF resistance in IBD**

A. Iannucci

15.20-15.30 **The IBD-associated L503F variant of organic cation transporter novel (OCTN-) 1 predicts a better response to anti-TNFALPHA in patients with ulcerative colitis: a single center analysis**

S. Parello

15.30-15.40 **Mapping the IL-3/ST2 AXIS in IBD: site-specific immune signatures in Crohn's disease and ulcerative colitis**

C. Pane

15.40-15.50 **A chronic model of experimental IBD reveals sarcopenia and long-term motor dysfunction**

S. Troisi

15.50-16.00 **Comparative outcomes of ulcerative colitis patients with MES 1 and histologic activity versus MES 2**
I. Faggiani

16.00-16.30 *Coffee break*

SESSION VI IBD IN THE EXTREMES

Chairs: S. Onali, A. Orlando

16.30-16.50 **Upper GI Crohn's disease**
L. Bertani

16.50-17.10 **Asymptomatic terminal ileitis**
A. Testa

17.10-17.30 **IBD in the rectum**
D. Pugliese

17.30-17.50 **Discussion**

LECTURE

Introduction: V. Annese

17.50-18.20 **Preclinical IBD: is it possible to predict disease onset?**
J. Torres

18.30-19.45 **ASSEMBLEA ORDINARIA DEI SOCI IG-IBD**

SESSION VII ORAL COMMUNICATIONS

Chairs: G. Bodini, G. Dragoni

08.30-08.40 **Crohn's disease exclusion diet (CDED) plus partial enteral nutrition versus oral steroids for induction and maintenance of remission in adult Crohn's disease: a prospective case-control study**

D.G. Ribaldone

08.40-08.50 **Effectiveness and safety of Mirikizumab in patients with moderate-to-severe ulcerative colitis: a real-life multicenter study**

F. Fanizzi

08.50-09.00 **Effectiveness and safety of Risankizumab in Crohn's disease patients from a large italian cohort: results from the RESOLVE IG-IBD study**

F. Di Vincenzo

09.00-09.10 **Beyond endoscopy: evaluating non-invasive tools for monitoring postoperative Crohn's disease recurrence**

L. Bertin

09.10-09.20 **Impact of type 2 diabetes on clinical outcomes and advanced therapy use in patients with Crohn's disease: a real-world propensity score-matched analysis**

S. Massironi

09.20-09.30 **Comparative effectiveness and safety of Tofacitinib and Filgotinib in patients with ulcerative colitis: a propensity score-weighted cohort study**

F.S. Macaluso

LECTURE

Introduction: M. Vecchi

09.30-10.00 **IBD and the autoimmune liver**
N. Gazzagon

10.00-10.30 *Coffee break*

LECTURE

Introduction: S. Danese

11.45-12.15 **Evolution of clinical trials in IBD**
V. Jairath

SESSION VIII ADVANCED THERAPY IN IBD: ONE SIZE DOES NOT FIT ALL (TO EACH HIS OWN)

Chairs: F.S. Macaluso, S. Saibeni

12.15-12.35 **There is no drug like the first**
G. Fiorino

12.35-12.55 **To each his own: second choices in Crohn's disease**
F.A. Caprioli

12.55-13.15 **To each his own: second choices in ulcerative colitis**
E.V. Savarino

13.15-13.30 **Discussion**

13.30-13.40 **Conclusions**

Questo evento è accreditato dal Provider Nazionale Health Meetings Group Srl (6083-460383 Ed.1) per le figure professionali del Biologo, Dietista, Infermiere e del Medico Chirurgo nelle discipline di Gastroenterologia, Medicina Interna, Chirurgia Generale, Anatomia Patologica, Pediatria, Pediatria (Pediatri di Libera Scelta), Scienza dell'Alimentazione e Dietetica.

L'evento prevede l'assegnazione di n. **3,6 CREDITI FORMATIVI**.

Si ricorda che l'acquisizione dei Crediti Formativi ECM è subordinata al rispetto di quanto segue:

- 90% di PRESENZA durante i lavori scientifici (rilevazione elettronica delle presenze)
- CONSEGNA del modulo di valutazione dell'evento e del modulo ANAGRAFICA
- APPARTENENZA alle discipline per le quali è stato richiesto l'accREDITAMENTO

Non è prevista verifica di apprendimento.

INFORMAZIONI SPONSOR

QUESTO EVENTO È REALIZZATO CON IL CONTRIBUTO
NON CONDIZIONANTE DI

abbvie

AGpharma

ALFASIGMA

biosphæra
PHARMA

CADIGROUP®
FARMACEUTICI

HEALTHCARE
CELLTRION

Lilly
A MEDICINE COMPANY

FERRING
PHARMACEUTICALS

GIULIANI

DyFalk

Johnson&Johnson

LIONHEALTH®
SOCIETÀ BENEFIT

MSD

Nestlé
HealthScience

Pfizer

Roche

SANDOZ

Takeda

teva

TILLOTTS PHARMA
ZERIA GROUP